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Abstract
The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization
of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple
standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality
medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups,
who were in a privileged position to witness the gap in quality of medicines between high-income countries and
low- and middle-income countries.
Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in
pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More
advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly
“involved” with medicines: regulators, international organizations, journalists, purchasers, prescribers, program
managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from
research and monitoring programs, and technical concepts should be translated in lay language through
communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines
needs the participation of all, and can only be successful if grounded in common understanding.
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Background
Over the last three decades, we have witnessed an
increasing globalization of pharmaceutical production.
The pharmaceutical ingredients and finished products
are manufactured in many different regions and coun-
tries, and they move on the international market
through multiple distribution channels. Unfortunately,
this shift has not been accompanied by a strengthening
and harmonization of the regulatory systems worldwide
[1]. As a result, the global pharmaceutical market is
characterized by a situation of multiple standards of
quality [2]. Many under-resourced National Regulatory
Authorities in low- and middle-income countries (LMICs)
lack the capacity to fully assure the quality of medicines
circulating in their territory, and the most vulnerable pop-
ulations are exposed to the risk of receiving poor-quality
medicines [3]. For instance, it is estimated that 34 % of
medicines in sub-Saharan Africa are of poor quality [4]. In
the field of malaria, the analysis of a database collating
customized summaries of 251 published anti-malarial
quality reports showed that out of 9,348 anti-malarials
sampled, 30.1 % (2,813) failed chemical/packaging
quality [5]. In addition, because of the complexity of
the supply channels in the global market and the
consequent difficulty to trace the origin of medicines,
poor-quality products may exceptionally reach high-
income countries, and in a few case they have even
been used in clinical trials [6].
Poor-quality medicines include substandard medicines,
i.e. genuine medicines that are produced by manufac-
turers authorized by a National Regulatory Authority
* Correspondence: rravinetto@itg.be
1QUAMED, Institute of Tropical Medicine, Antwerp, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ravinetto et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:36 
DOI 10.1186/s40545-016-0088-0
but do not meet quality specifications, and falsified or
counterfeit medicines, i.e. medicines deliberately and
fraudulently mislabeled with respect to identity and/or
source. While in case of falsified medicines there is a delib-
erate (criminal) willingness to fraud, substandard medicines
result from human error or negligence at manufacturing
sites. Consequently, corrective actions are very different:
falsified medicines can be fought by repressing illegal
manufacturing and distribution, while substandard medi-
cines may only be tackled by strengthening the capacities of
National Regulatory Authorities [7]. Noteworthy, since
there is currently no universally agreed definition of ‘coun-
terfeit medicine’, the World Health Organization (WHO)
has adopted since 2012 the broader wording “substandard,
spurious, falsely labelled, falsified and counterfeit” (SSFFC)
medical products, and this “until a new definition is agreed”
(http://www.who.int/medicines/regulation/ssffc/definitions/
en/). However, irrespectively of definitions, there are no
differences in what concerns the risks for the patients, i.e.
therapeutic failure, toxicity and/or emergence of resistance,
all leading to a great deal of avoidable human suffering,
including possibly death.
Among those who first raised the alarm about the weak-
ness of pharmaceutical quality assurance in LMICs, there
were pharmacists working in humanitarian medical pro-
jects [8]. They were in a privileged position to witness the
gap between their own countries (at that time, mostly
humanitarian workers came from Western countries) and
the LMICs where humanitarian projects were carried
out. They raised awareness among the various stake-
holders, well beyond their own organizations, and they
contributed to pushing international organizations and
researchers to further investigate the extent of the prob-
lem. Importantly, the need to overcome the ethically un-
acceptable divide between High-Income Countries and
LMICs led pioneer “humanitarian pharmacists” to look
for multidisciplinary collaborations, including with the
academia. This was the case of Jacques Pinel, who actively
disseminated the lessons from the field through different
networks and tools, including peer-reviewed journals and
academic textbooks [2, 9].
Positive signals and persisting gaps
Some positive signals show that there is an increasing
attention for the threats to individual and public health
represented by poor-quality medicines. For instance, the
World Health Organization (WHO) launched in 2001 the
Prequalification (PQ) Programme, which had a major
positive impact for assuring the quality of HIV/AIDS,
malaria and tuberculosis medicines in LMICs [10]. The
African Medicines Regulatory Harmonization Initiative
was started in 2009 to increase access to safe and
effective medicines of good quality [11], and the estab-
lishment of an African Medicines Agency is underway,
“to ensure that all Africans have access to affordable
medical products for priority diseases/conditions that
meet internationally-recognized standards of quality,
safety and efficacy” [12]. Other initiatives include
QUAMED, a network of non-governmental organiza-
tions and sub-Saharan African procurement centers
that pool resources for auditing distributors and manu-
facturers according to the WHO standards and share
the gained knowledge [13]; the WWARN Medicine
Quality Scientific Group, that shares expertise and
collates information to increase understanding of the
prevalence and distribution of poor-quality medicines
[14]; and the joint project of the United States
Pharmacopoeia and USAID to promote quality of medi-
cines in developing countries, that strengthens quality
assurance systems and quality control laboratories [15].
Importantly, the Sustainable Development Goal 3.8
aims at universal health coverage, including quality and
affordable essential medicines and vaccines for all. To
achieve this global aim, different interventions are
needed at different levels, by broadening or replicating
the positive initiatives listed above. Among others, the
National Regulatory Authorities in LMICs should be
strengthened, the information available on quality of
medicines should be transparently shared, the WHO
Prequalification Programme should be broadened to all
the medicines included in the WHO Essential Medicines
Model List, and the procurement policies of major
donors and procurement agencies should be adapted to
promote a uniform reference to WHO standards. But
the process remains slow, and many communities are
still exposed to avoidable risks, not only due to the il-
legal, falsified medicines, but especially due to legitimate
sub-standards [7]. This reality is not limited to Sub-
Saharan Africa. For instance, in Pakistan a case of cross-
contamination during the manufacturing process was
discovered after the contaminated medicine caused the
death of 120 patients [16]. A recent cross-sectional study
carried out in China to investigate the content in active
ingredient of five antimicrobial drugs found that all
tested samples were registered in the country, but 15 %
failed to meet the Chinese Pharmacopeia standard [17].
The role of advocacy and pedagogy
Despite the increasing evidence that weaknesses in
pharmaceutical quality assurance have been causing a
great deal of avoidable morbidity and mortality, aware-
ness remains quite low among non-specialists, including
academics and policy makers. For instance, substandard
antibiotics are likely to be a powerful contributor to the
emergence of resistances, since they may be under-
dosed or poorly bioavailable, resulting in sub-therapeutic
doses. However, their role is frequently downplayed in
policy documents concerning the global fight against
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antimicrobial resistance, e.g. the list of interventions pro-
posed in the recent report “Tackling drug-resistant infec-
tions globally: final recommendations” [18] does not
include a specific action concerning the fight against
poor-quality antibiotics. We formulate the hypothesis that
this is at least partly due to the fact that pharmaceutical
regulation is still insufficiently or inadequately addressed
in the study curricula of future policy makers. Thus, also
the deleterious consequences of poor pharmaceutical
regulation on health systems and public health tend to be
neglected.
In this scenario, more and broader advocacy is needed
for universal access to quality-assured medicines, targeting
all those who are differently “involved” with medicines:
regulators, international organizations, journalists, pur-
chasers, prescribers, program managers, policy makers,
public health actors and, obviously, those who are directly
exposed to the consequences of inadequate practices and
policies: the patients.
Advocacy should be based on strong evidence from re-
search and monitoring programs. A lot has been published,
even recently [19–22], but the methodology is not always
consistent across studies, and some geographic regions
have been neglected by the researchers [5]. On a positive
note, the WHO recently published new guidelines on the
conduct of surveys of the quality of medicines [23], which
provide National Regulatory Authorities, international
organizations, procurement agents, nongovernmental orga-
nizations and academic or research groups with a robust
methodology. Results of well-conducted surveys will help
to better evaluate the prevalence of poor-quality medicines
in specific countries/regions, to identify the specific weak-
nesses along the supply chain, and to design tailored
corrective actions. In addition, by documenting the extent
of the problem, these studies would provide an important
evidence-based support for advocacy.
But academic articles and technical paper can be difficult
to understand for non-specialists. Adequate communica-
tion tools should be developed, in lay language, to address
those who do not have a technical background in quality
assurance of medicines, but may play an important role in
defining policies and/or in advocating for universal access
to quality-assured medicines. Jacques Pinel, who passed
away in 2015, was acquainted with the difficulties of
dialoguing with a variety of counterparts that rarely share
the same technical knowledge. An important lesson that we
should retain from his work [24] is that continuing educa-
tion, and dissemination of information on pharmaceutical
regulation and standards in a language comprehensible
to all, are essential for an effective advocacy in the fight
against the epidemic of poor-quality medicines in
LMICs. The importance of giving accurate information
in lay language is demonstrated by the experience of
the advocates of access to medicines. They managed to
make complex intellectual property issues understand-
able by the scientific and international community, so
creating a powerful advocacy movement which has
been able to trigger important changes [25].
Conclusion
The development and dissemination of communication
tools for explaining in lay language the meaning of
"medicines quality", the factors enhancing or hindering
it, and the consequences of poor-quality medicines for
individual and public health, is needed to foster advo-
cacy and to create a favorable environment for policy
changes. The fight to ensure universal access to quality
medicines needs the participation of all, and can only be
successful if grounded in common understanding.
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